

PRIOR AUTHORIZATION REQUEST

Global Quantity Limit

Patient Information:

Name:					
Membe	er ID:				
Addres	s:				
City, St	ate, Zip:				
Date of	Birth:				
Dragari	har Infarn	nation			
	ber Inforn	nation:			
Name:					
NPI:	Numahaw				
Fax Nu	Number:				
Addres					
City, St	ate, Zip:				
Reques	sted Medic	cation			
Rx Nan					
Rx Stre	ength				
Rx Quantity:					
	quency:				
Rx Rou					
Administration:					
Diagno	sis and ICE	Code:			
prescribe quantities Upon red	ed a medicate can be proceed to the one of t	ion for your vided. Plea completed	efit requires that we review certain requests for coverage with the patient that requires Prior Authorization before benefit coverage or use complete the following questions then fax this form to the toll-freed form, prescription benefit coverage will be determined based to the that supporting clinical documentation is required.	coverage of number lis on the pla	f additiona sted below an's rules
1	Is this a red document t	quest for INI7 the diagnosis	FIAL or CONTINUATION of therapy with the requested medication? Please or indication AND the quantity for the requested medication per 12 months:		
	[] INITIAL (If checked, g	10 to 4)		
	[] CONTIN	UATION (If c	hecked, go to 2)		
2		tient been co urther questic	ompliant with the treatment regimen? ons.]	Yes	No
3	Has the patient had a response to treatment? [No further questions.] Yes			Yes	No
4	Is this requ	est for quant	tities that EXCEED the maximum dose established by the FDA for the		

If you have any questions, call: 1-888-258-8250

PRIOR AUTHORIZATION REQUEST

	requested medication? [] Yes (If checked, go to 5)		
	[] No (If checked, go to 10)		
5	Did the patient have an inadequate response to the same medication at a LOWER dosage? [If no, no further questions.]	Yes	No
6	Was medication non-adherence ruled out as a reason for the inadequate response? [If no, no further questions.]	Yes	No
7	Is the patient tolerating the medication at a lower dosage? [If no, no further questions.]	Yes	No
8	Is there documentation of a peer-reviewed journal article that demonstrates the safety and efficacy of the requested dose for the indication? [If yes, no further questions.]	Yes	No
9	Is the requested quantity and dosing supported in medical-accepted compendia? [No further questions.]	Yes	No
	[NOTE: This question must be answered by the prescriber/prescriber's office.]		
10	Is this request for quantities of a LOWER strength that DO NOT EXCEED the maximum dose established by the FDA for the requested medication (for example, two 30mg tablets/day in place of one 60mg tablet/day)? [] Yes (If checked, go to 11)		
	[] No (If checked, go to 15)		
11	Is the dosing due to inadequate response to the optimized dose? [If yes, no further questions.]	Yes	No
	[NOTE: Dose optimization is the use of a higher strength to allow a patient to take fewer doses to achieve the same total daily dose.]		
12	Is the dosing due to patient inability to tolerate total daily dose in one administration? [If yes, no further questions.]	Yes	No
13	Is the dosing based on inability to swallow optimal dose? [If yes, no further questions.]	Yes	No
14	Is there a manufacturer shortage on the optimized strength? [No further questions.]	Yes	No
15	Is this request for quantities for a medication that does NOT have a maximum dose as established by the FDA? [If no, no further questions.]	Yes	No
16	Did the patient have an inadequate response to the SAME medication at a LOWER dosage? [If no, no further questions.]	Yes	No
17	Is the patient tolerating the medication at a LOWER dosage? [If no, no further questions.]	Yes	No



PRIOR AUTHORIZATION REQUEST

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

FAX COMPLETED FORM TO: 1-833-896-0656

DATE

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

PHYSICIAN SIGNATURE

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.